References
- Sieff CA. Hematopoietic growth factors. J Clin Invest 1987; 79: 1549–1557
- Cannistra SA, Griffin GD. Regulation of the production and function of granulocytes and monocytes. Sem Hematol 1988; 25: 173–188
- Metcalf D. Hemopoietic growth factors. 2. Clinical applications. Lancet 1989; 335: 885–887
- Biesma B, Willemse P HB, Mulder NH. Effects of interleukin-3 after chemotherapy for advanced breast cancer. Blood 1992; 80: 1141–1148
- Dedhar S, Gaboury L, Galloway P, Eaves C. Human G-CSF is a growth factor active on a variety of cell types of nonhemopoietic origin. Proc Natl Acad Sci USA 1988; 85: 9253–9257
- Berdel WE, Danhauser-Riedl S, Steinhauser G, Winton EF. Various human hematopoietic growth factors (IL3, GM-CSF, G-CSF) stimulate clonal growth of nonhematopoietic tumor cells. Blood 1989; 73: 80–83
- Bussolino F, Wang JM, DeFilippi P. G- and GM-CSF induce human endothelial cells to migrate and proliferate. Nature 1989; 337: 471–472
- Baldwin GC, Gasson JC, Kaurfman SE. Non hematopoietic tumor cells express functional GM-CSF receptor. Blood 1989; 73: 1033–1037
- Vallenga E, Biesma A., Meyer C, Teveld WA, Esselink M, DeVries GE. The effects of five hemopoietic growth factors on human SCLC cell lines: IL3 enhances the proliferation of one of the eleven cell lines. Cancer Res 1991; 51: 73–76
- Yamashita Y, Nara N, Aoki N. Antiproliferative and differentiative effects of GM-CSF on a variant human SCLC cell line. Cancer Res 1989; 49: 5334–5338
- Twentyman PR, Wright KA. Failure of GM-CSF to influence the growth of small cell and non-small cell lung cancer cell lines in vitro. Eur J Cancer 1991; 27: 6–8
- Begg AC, McNally NJ, Shrive DC, Karcher H. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 1985; 6: 620–626
- Schwab M, Alitalo K, Klempnauer KH. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumor. Nature 1983; 305: 245–248
- Alitalo K, Schwab M, Lin CC, Bishop JM. Homogeneously staining chromosomal regions contain amplified copies of abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrin cells from a human colon carcinoma. Proc Natl Acad Sci USA 1983; 80: 1707–1709
- Piechaczyc M., Blanchard JM, Marty L. Post transcriptional regulation of glyceraldehyde-3-phosphate-dehydrogenase gene expression in rat tissue. Nucleic Acids Res 1984; 12: 6951–6960
- Ruff MR, Farrar WL, Pert CB. IFN gamma and GM-CSF inhibit growth and induce antigens characteristic of myeloid differentiation in SCLC. Proc Natl Acad Sci USA 1986; 83: 6613–6617
- Foulke RS, Marshall MH, Trotta PP, Von Hoff DD. In vitro assessment of the effects of GM-CSF on primary human tumors and derived lines. Cancer Res 1990; 50: 6264–6267
- Filmus J, Buick RN. Relationship of c-myc expression to differentiation and proliferation of HL60 cells. Cancer Res 1985; 45: 822–825
- Griep AE, DeLuca HF. Decreased c-myc expression is an early event in retinoic acid-induced differentiation of F9 teratocarcinoma cells. Proc Natl Acad Sci USA 1986; 83: 5539–5543
- Park LS, Friend D, Price V. Heterogeneity in human IL3 receptors: A subclass that binds human GM-CSF. J Biol Chem 1989; 264: 5420–5427
- Budel LM, Elbaz O, Hogerbrugge H. Common binding structure of GM-CSF and IL3 in human acute myeloid leukemia cells and monocytes. Blood 1990; 75: 1439–1445